peripheral T-cell lymphoma
Conditions
Interventions
study group:pralatrexate combined with chidamide and azacitidine
Sponsors
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1.According to the WHO Fifth Edition Classification of Lymphoid and Haematopoietic Tumors, the patient's pathological diagnosis corresponds to the following subtypes of Peripheral T-cell Lymphoma (PTCL): Peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) Anaplastic large cell lymphoma, ALK-negative (ALCL, ALK-) Nodal follicular helper T-cell lymphoma (including angioimmunoblastic, follicular, and not otherwise specified variants) Hepatosplenic T-cell lymphoma (HSTCL) Enteropathy-associated T-cell lymphoma (EATL) Monomorphic epitheliotropic intestinal T-cell lymphoma (MEITL) Intestinal T-cell lymphoma, not otherwise specified (ITCL-NOS); 2.Aged between 18 and 80 years old; 3.PTCL patients diagnosed for the first time, who have not received radiotherapy, chemotherapy or other treatments; 4.PET-CT or CT/MRI shows at least one measurable lesion in two dimensions (longest diameter > 1.5 cm); 5.Women of childbearing age must have a negative pregnancy test result and be willing to use effective contraception during the study period and for at least 12 months after the last dose of study medication; pregnant and breastfeeding women are excluded; all male participants must use contraception during the study period and for at least 3 months after the last dose of study medication; 6.Who can provide informed consent and understand and comply with all study requirements;
Exclusion criteria
Exclusion criteria: 1.Severe mental illness; 2.HIV infection; 3.Individuals with severe renal dysfunction (glomerular filtration rate 20); 5.History of other active malignancies; 6.Pregnant or lactating women; 7.Unable to understand or comply with the research protocol;
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival;safety; | — |
Secondary
| Measure | Time frame |
|---|---|
| overall survival;partial remission rate;overall response rate;complete remission rate; | — |
Countries
China
Contacts
Public ContactHongyan Tong
The FIrst Affiliated Hospital, College of Medicine, Zhejiang University
Outcome results
None listed